S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
The Growing Case For A Major Stock Market Correction
Tech Stocks to Sink Your Teeth into in 2022
3 Trustworthy High-Yield Dividend Stocks to Buy Now
3 Heavily Shorted Stocks With Squeeze Potential
3 Financially Fit Airline Stocks Worth Boarding
Should You Buy The Dip In JPMorgan (NYSE: JPM) Stock?
United Health’s Guidance Gives Investors A Chill 
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
The Growing Case For A Major Stock Market Correction
Tech Stocks to Sink Your Teeth into in 2022
3 Trustworthy High-Yield Dividend Stocks to Buy Now
3 Heavily Shorted Stocks With Squeeze Potential
3 Financially Fit Airline Stocks Worth Boarding
Should You Buy The Dip In JPMorgan (NYSE: JPM) Stock?
United Health’s Guidance Gives Investors A Chill 
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
The Growing Case For A Major Stock Market Correction
Tech Stocks to Sink Your Teeth into in 2022
3 Trustworthy High-Yield Dividend Stocks to Buy Now
3 Heavily Shorted Stocks With Squeeze Potential
3 Financially Fit Airline Stocks Worth Boarding
Should You Buy The Dip In JPMorgan (NYSE: JPM) Stock?
United Health’s Guidance Gives Investors A Chill 
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
The Growing Case For A Major Stock Market Correction
Tech Stocks to Sink Your Teeth into in 2022
3 Trustworthy High-Yield Dividend Stocks to Buy Now
3 Heavily Shorted Stocks With Squeeze Potential
3 Financially Fit Airline Stocks Worth Boarding
Should You Buy The Dip In JPMorgan (NYSE: JPM) Stock?
United Health’s Guidance Gives Investors A Chill 
NASDAQ:AKER

Akers Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$4.48
-0.38 (-7.82%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.43
▼
$5.10
50-Day Range
$2.47
▼
$4.59
52-Week Range
$1.65
▼
$6.97
Volume
118,547 shs
Average Volume
769,876 shs
Market Capitalization
$74.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.3

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Akers Biosciences logo

About Akers Biosciences

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

Headlines

Historically fast healer Cam Akers hopes to put hurt on Bucs defense
January 19, 2022 |  msn.com
Budda Baker injury update: Cardinals safety released from hospital after collision with Rams' Cam Akers, shares video message
January 19, 2022 |  msn.com
Cam Akers says he feels 100 percent, wants to prove it on field
January 14, 2022 |  msn.com
Hot on his heels: Cam Akers back from Achilles tear for Rams
January 14, 2022 |  msn.com
Inside Cam Akers’ remarkable return from the most feared injury in sports
January 13, 2022 |  msn.com
Watch: Cam Akers was mic'd up for his miraculous return from Achilles injury
January 11, 2022 |  msn.com
Beyoncé’s Stylist Zerina Akers On Changing Her Career And Becoming A Trailblazing Force In Fashion
January 10, 2022 |  msn.com
Highlights from Cam Akers’ rookie campaign ahead of his 2021 debut
January 7, 2022 |  msn.com
NFL World Reacts To Wednesday’s Cam Akers News
January 5, 2022 |  msn.com
Cam Akers has full practice Wednesday, set to play Sunday
January 5, 2022 |  msn.com
Sean McVay uncertain of what Cam Akers' workload will look like
January 5, 2022 |  msn.com
Rams RB Cam Akers Expected to Play Sunday vs. 49ers, Coach McVay Says
January 4, 2022 |  msn.com
The Worldwide Cholesterol Testing Industry is Expected to Reach $18.2 Billion by 2027 - ResearchAndMarkets.com
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKER
Previous Symbol
CUSIP
N/A
CIK
1321834
Web
www.akersbio.com
Phone
856 848 8698
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.58 million
Price / Sales
47.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.38 per share
Price / Book
0.83

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-3.89 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.42%
Return on Assets
-73.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.22
Quick Ratio
9.22

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
16,653,000
Free Float
N/A
Market Cap
$74.61 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2018
Today
1/20/2022

MarketRank™

Overall MarketRank™

1.08 out of 5 stars

Medical Sector

1243rd out of 1,415 stocks

Diagnostic Substances Industry

22nd out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

Is Akers Biosciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akers Biosciences in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" Akers Biosciences stock.
View analyst ratings for Akers Biosciences or view top-rated stocks.

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) posted its quarterly earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.
View Akers Biosciences' earnings history.

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the following people:
  • Mr. Christopher C. Schreiber, CEO, Pres & Director (Age 56, Pay $507.62k)
  • Mr. Ian Rhodes, Interim Chief Financial Officer (Age 48)
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 65)

What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO?

3 employees have rated Akers Biosciences CEO Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among Akers Biosciences' employees.

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu Biopharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $4.48.

How much money does Akers Biosciences make?

Akers Biosciences has a market capitalization of $74.61 million and generates $1.58 million in revenue each year.

How many employees does Akers Biosciences have?

Akers Biosciences employs 4 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

Where are Akers Biosciences' headquarters?

Akers Biosciences is headquartered at 201 GROVE RD, THOROFARE NJ, 08086.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856 848 8698 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.